Oxidative stress and metabolic syndrome: Cause or consequence of Alzheimer's disease?

Oxidative Medicine and Cellular Longevity

Volumn 2014, Issue , 2014, Pages

  Luque Contreras, Diana ^a   Carvajal, Karla ^b   Toral Rios, Danira ^c   Franco Bocanegra, Diana ^d   Campos Peña, Victoria ^e  

^a UNIVERSIDAD AUTÓNOMA DE COAHUILA   (Mexico)

^b INSTITUTO NACIONAL DE PEDIATRÍA   (Mexico)

^c DEPARTAMENTO DE FÍSICA   (Mexico)

^d UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^e NATIONAL INSTITUTE OF NEUROLOGY AND NEUROSURGERY   (Mexico)

Author keywords

[No Author keywords available]

Indexed keywords

ALZHEIMER DISEASE; COMPLICATION; HUMAN; METABOLIC SYNDROME X; METABOLISM; MITOCHONDRION; OXIDATIVE STRESS; PATHOLOGY; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; VASCULAR ENDOTHELIUM;

ALZHEIMER DISEASE; ENDOTHELIUM, VASCULAR; HUMANS; METABOLIC SYNDROME X; MITOCHONDRIA; OXIDATIVE STRESS; RENIN-ANGIOTENSIN SYSTEM;

EID: 84893834710     PISSN: 19420900     EISSN: 19420994     Source Type: Journal    
DOI: 10.1155/2014/497802     Document Type: Review

References (96)

1. Moreira P. I., Nunomura A., Nakamura M., Takeda A., Shenk J. C., Aliev G., Smith M. A., Perry G., Nucleic acid oxidation in Alzheimer disease. Free Radical Biology and Medicine 2008 44 8 1493 1505 2-s2.0-41149166082 10.1016/j.freeradbiomed.2008.01.002
2. Ashe K. H., Zahs K. R., Probing the biology of Alzheimer's disease in mice. Neuron 2010 66 5 631 645 2-s2.0-77953675879 10.1016/j.neuron.2010.04.031
3. Zahs K. R., Ashe K. H., beta-Amyloid oligomers in aging and Alzheimer's disease. Frontiers in Aging Neuroscience 2013 5 28
4. Sakono M., Zako T., Amyloid oligomers: formation and toxicity of A β oligomers. The FEBS Journal 2010 277 6 1348 1358 2-s2.0-77749308402 10.1111/j.1742-4658.2010.07568.x
5. Walsh D. M., Selkoe D. J., Oligomers in the brain: the emerging role of soluble protein aggregates in neurodegeneration. Protein and Peptide Letters 2004 11 3 213 228 2-s2.0-2542427690 10.2174/0929866043407174 (Pubitemid 38689025)
6. Puzzo D., Privitera L., Leznik E., Fà M., Staniszewski A., Palmeri A., Arancio O., Picomolar amyloid- β positively modulates synaptic plasticity and memory in hippocampus. Journal of Neuroscience 2008 28 53 14537 14545 2-s2.0-58149385218 10.1523/JNEUROSCI.2692-08.2008
7. Puzzo D., Privitera L., Palmeri A., Hormetic effect of amyloid-beta peptide in synaptic plasticity and memory. Neurobiology of Aging 2012 33 7 e15 e24 2-s2.0-84856070705 10.1016/j.neurobiolaging.2011.12.020
8. Koffie R. M., Hyman B. T., Spires-Jones T. L., Alzheimer's disease: synapses gone cold. Molecular Neurodegeneration 2011 6 1 63 2-s2.0-80052027401 10.1186/1750-1326-6-63
9. Reddy P. H., Beal M. F., Amyloid beta, mitochondrial dysfunction and synaptic damage: implications for cognitive decline in aging and Alzheimer's disease. Trends in Molecular Medicine 2008 14 2 45 53 2-s2.0-39149122810 10.1016/j.molmed.2007.12.002
10. Butterfield D. A., Boyd-Kimball D., The critical role of methionine 35 in Alzheimer's amyloid β -peptide (1-42)-induced oxidative stress and neurotoxicity. Biochimica et Biophysica Acta 2005 1703 2 149 156 2-s2.0-12844266117 10.1016/j.bbapap.2004.10.014 (Pubitemid 40170438)
11. Butterfield D. A., Bush A. I., Alzheimer's amyloid β -peptide (1-42): involvement of methionine residue 35 in the oxidative stress and neurotoxicity properties of this peptide. Neurobiology of Aging 2004 25 5 563 568 2-s2.0-1842519391 10.1016/j.neurobiolaging.2003.12.027 (Pubitemid 38686475)
12. Butterfield D. A., Kanski J., Methionine residue 35 is critical for the oxidative stress and neurotoxic properties of Alzheimer's amyloid β -peptide 1-42. Peptides 2002 23 7 1299 1309 2-s2.0-0035997233 10.1016/S0196-9781(02)00066-9 (Pubitemid 34786708)
13. Butterfield D. A., Drake J., Pocernich C., Castegna A., Evidence of oxidative damage in Alzheimer's disease brain: central role for amyloid β -peptide. Trends in Molecular Medicine 2001 7 12 548 554 2-s2.0-0035194145 10.1016/S1471-4914(01)02173-6 (Pubitemid 33127140)
14. Weingarten M. D., Lockwood A. H., Hwo S. Y., Kirschner M. W., A protein factor essential for microtubule assembly. Proceedings of the National Academy of Sciences of the United States of America 1975 72 5 1858 1862 2-s2.0-0008538685
15. Goedert M., Spillantini M. G., Jakes R., Rutherford D., Crowther R. A., Multiple isoforms of human microtubule-associated protein tau: sequences and localization in neurofibrillary tangles of Alzheimer's disease. Neuron 1989 3 4 519 526 2-s2.0-0024745894
16. Brandt R., Léger J., Lee G., Interaction of tau with the neural plasma membrane mediated by tau's amino-terminal projection domain. Journal of Cell Biology 1995 131 5 1327 1340 2-s2.0-0028785525 10.1083/jcb.131.5.1327
17. Goode B. L., Denis P. E., Panda D., Radeke M. J., Miller H. P., Wilson L., Feinstein S. C., Functional interactions between the proline-rich and repeat regions of tau enhance microtubule binding and assembly. Molecular Biology of the Cell 1997 8 2 353 365 2-s2.0-0031035402 (Pubitemid 27097949)
18. Mukrasch M. D., Biernat J., von Bergen M., Griesinger C., Mandelkow E., Zweckstetter M., Sites of tau important for aggregation populate β -structure and bind to microtubules and polyanions. Journal of Biological Chemistry 2005 280 26 24978 24986 2-s2.0-21644446496 10.1074/jbc.M501565200 (Pubitemid 40934590)
19. Braak H., Braak E., Neuropathological stageing of Alzheimer-related changes. Acta Neuropathologica 1991 82 4 239 259 2-s2.0-0025863618
20. Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Identification of oligomers at early stages of tau aggregation in Alzheimer's disease. The FASEB Journal 2012 26 5 1946 1959
21. Patterson K. R., Remmers C., Fu Y., Brooker S., Kanaan N. M., Vana L., Ward S., Reyes J. F., Philibert K., Glucksman M. J., Binder L. I., Characterization of prefibrillar tau oligomers in vitro and in Alzheimer disease. Journal of Biological Chemistry 2011 286 26 23063 23076 2-s2.0-79959571777 10.1074/jbc.M111.237974
22. Rapoport S. I., Coupled reductions in brain oxidative phosphorylation and synaptic function can be quantified and staged in the course of Alzheimer disease. Neurotoxicity Research 2003 5 6 385 397 2-s2.0-1342269756 10.1007/BF03033167
23. Lasagna-Reeves C. A., Castillo-Carranza D. L., Sengupta U., Clos A. L., Jackson G. R., Kayed R., Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. Molecular Neurodegeneration 2011 6, article 39 2-s2.0-79957913270 10.1186/1750-1326-6-39
24. Martin L., Latypova X., Terro F., Post-translational modifications of tau protein: implications for Alzheimer's disease. Neurochemistry International 2011 58 4 458 471 2-s2.0-79952105548 10.1016/j.neuint.2010.12.023
25. Quintanilla R. A., Matthews-Roberson T. A., Dolan P. J., Johnsion G. V. W., Caspase-cleaved tau expression induces mitochondrial dysfunction in immortalized cortical neurons: implications for the pathogenesis of Alzheimer disease. Journal of Biological Chemistry 2009 284 28 18754 18766 2-s2.0-67650556426 10.1074/jbc.M808908200
26. Lasagna-Reeves C. A., Castillo-Carranza D. L., Guerrero-Muñoz M. J., Jackson G. R., Kayed R., Preparation and characterization of neurotoxic tau oligomers. Biochemistry 2010 49 47 10039 10041 2-s2.0-78649503285 10.1021/bi1016233
27. Ferrari A., Hoerndli F., Baechi T., Nitsch R. M., Götz J., β -amyloid induces paired helical filament-like tau filaments in tissue culture. Journal of Biological Chemistry 2003 278 41 40162 40168 2-s2.0-0141960033 10.1074/jbc.M308243200 (Pubitemid 37248584)
28. Good P. F., Perl D. P., Bierer L. M., Schmeidler J., Selective accumulation of aluminum and iron in the neurofibrillary tangles of Alzheimer's disease: a laser microprobe (LAMMA) study. Annals of Neurology 1992 31 3 286 292 2-s2.0-0026573467
29. Smith M. A., Harris P. L. R., Sayre L. M., Perry G., Iron accumulation in Alzheimer disease is a source of redox-generated free radicals. Proceedings of the National Academy of Sciences of the United States of America 1997 94 18 9866 9868 2-s2.0-0030885482 10.1073/pnas.94.18.9866 (Pubitemid 27408156)
30. Resende R., Moreira P. I., Proença T., Deshpande A., Busciglio J., Pereira C., Oliveira C. R., Brain oxidative stress in a triple-transgenic mouse model of Alzheimer disease. Free Radical Biology and Medicine 2008 44 12 2051 2057 2-s2.0-43849096294 10.1016/j.freeradbiomed.2008.03.012
31. Su B., Wang X., Lee H.-G., Tabaton M., Perry G., Smith M. A., Zhu X., Chronic oxidative stress causes increased tau phosphorylation in M17 neuroblastoma cells. Neuroscience Letters 2010 468 3 267 271 2-s2.0-72249109630 10.1016/j.neulet.2009.11.010
32. Liu Q., Smith M. A., Avilá J., DeBernardis J., Kansal M., Takeda A., Zhu X., Nunomura A., Honda K., Moreira P. I., Oliveira C. R., Santos M. S., Shimohama S., Aliev G., De La Torre J., Ghanbari H. A., Siedlak S. L., Harris P. L. R., Sayre L. M., Perry G., Alzheimer-specific epitopes of tau represent lipid peroxidation-induced conformations. Free Radical Biology and Medicine 2005 38 6 746 754 2-s2.0-13844267510 10.1016/j.freeradbiomed.2004.11.005 (Pubitemid 40249745)
33. Zhang Y.-J., Xu Y.-F., Liu Y.-H., Yin J., Li H.-A., Wang Q., Wang J.-Z., Peroxynitrite induces Alzheimer-like tau modifications and accumulation in rat brain and its underlying mechanisms. The FASEB Journal 2006 20 9 1431 1442 2-s2.0-33746508651 10.1096/fj.05-5223com (Pubitemid 44943851)
34. Mahley R. W., Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science 1988 240 4852 622 630 2-s2.0-0024299370
35. Hatters D. M., Peters-Libeu C. A., Weisgraber K. H., Apolipoprotein E structure: insights into function. Trends in Biochemical Sciences 2006 31 8 445 454 2-s2.0-33746311471 10.1016/j.tibs.2006.06.008 (Pubitemid 44108662)
36. Corder E. H., Saunders A. M., Strittmatter W. J., Schmechel D. E., Gaskell P. C., Small G. W., Roses A. D., Haines J. L., Pericak-Vance M. A., Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 1993 261 5123 921 923 2-s2.0-0027194791 (Pubitemid 23275809)
37. Munson G. W., Roher A. E., Kuo Y.-M., Gilligan S. M., Reardon C. A., Getz G. S., LaDu M. J., SDS-stable complex formation between native apolipoprotein E3 and β -amyloid peptides. Biochemistry 2000 39 51 16119 16124 2-s2.0-0034719129 10.1021/bi0017475 (Pubitemid 32038274)
38. Holtzman D. M., Role of apoE/A β interactions in the pathogenesis of Alzheimer's disease and cerebral amyloid angiopathy. Journal of Molecular Neuroscience 2001 17 2 147 155 2-s2.0-0034746840 10.1385/JMN:17:2:147 (Pubitemid 33063519)
39. Holtzman D. M., Bales K. R., Tenkova T., Fagan A. M., Parsadanian M., Sartorius L. J., Mackey B., Olney J., McKeel D., Wozniak D., Paul S. M., Apolipoprotein E isoform-dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proceedings of the National Academy of Sciences of the United States of America 2000 97 6 2892 2897 2-s2.0-4243215848 10.1073/pnas.050004797 (Pubitemid 30159268)
40. Ye S., Huang Y., Müllendorff K., Dong L., Giedt G., Meng E. C., Cohen F. E., Kuntz I. D., Weisgraber K. H., Mahley R. W., Apolipoprotein (apo) E4 enhances amyloid β peptide production in cultured neuronal cells: ApoE structure as a potential therapeutic target. Proceedings of the National Academy of Sciences of the United States of America 2005 102 51 18700 18705 2-s2.0-29444460533 10.1073/pnas.0508693102 (Pubitemid 43011289)
41. Hayek T., Oiknine J., Brook J. G., Aviram M., Increased plasma and lipoprotein lipid peroxidation in apo E-deficient mice. Biochemical and Biophysical Research Communications 1994 201 3 1567 1574 2-s2.0-0028059454 10.1006/bbrc.1994.1883 (Pubitemid 24234268)
42. Shea T. B., Rogers E., Ashline D., Ortiz D., Sheu M.-S., Apolipoprotein E deficiency promotes increased oxidative stress and compensatory increases in antioxidants in brain tissue. Free Radical Biology and Medicine 2002 33 8 1115 1120 2-s2.0-0037108213 10.1016/S0891-5849(02)01001-8
43. Miyata M., Smith J. D., Apolipoprotein E allele-specific antioxidant activity and effects on cytotoxicity by oxidative insults and β -amyloid peptides. Nature Genetics 1996 14 1 55 61 2-s2.0-0029765553 10.1038/ng0996-55 (Pubitemid 26301547)
44. Kharrazi H., Vaisi-Raygani A., Rahimi Z., Tavilani H., Aminian M., Pourmotabbed T., Association between enzymatic and non-enzymatic antioxidant defense mechanism with apolipoprotein E genotypes in Alzheimer disease. Clinical Biochemistry 2008 41 12 932 936 2-s2.0-47049127899 10.1016/j.clinbiochem.2008. 05.001
45. Lauderback C. M., Kanski J., Hackett J. M., Maeda N., Kindy M. S., Butterfield D. A., Apolipoprotein E modulates Alzheimer's A β (1-42)-induced oxidative damage to synaptosomes in an allele-specific manner. Brain Research 2002 924 1 90 97 2-s2.0-0037016321 10.1016/S0006-8993(01)03228-0 (Pubitemid 34017468)
46. Ramassamy C., Averill D., Beffert U., Bastianetto S., Theroux L., Lussier-Cacan S., Cohn J. S., Christen Y., Davignon J., Quirion R., Poirier J., Oxidative damage and protection by antioxidants in the frontal cortex of Alzheimer's disease is related to the apolipoprotein E genotype. Free Radical Biology and Medicine 1999 27 5-6 544 553 2-s2.0-0032817968 10.1016/S0891- 5849(99)00102-1 (Pubitemid 29408640)
47. Tchantchou F., Graves M., Rogers E., Ortiz D., Shea T. B., N-acteyl cysteine alleviates oxidative damage to central nervous system of ApoE-deficient mice following folate and vitamin E-deficiency. Journal of Alzheimer's Disease 2005 7 2 135 180 2-s2.0-17844394677
48. Huebbe P., Jofre-Monseny L., Boesch-Saadatmandi C., Minihane A.-M., Rimbach G., Effect of apoE genotype and vitamin E on biomarkers of oxidative stress in cultured neuronal cells and the brain of targeted replacement mice. Journal of Physiology and Pharmacology 2007 58 4 683 698 2-s2.0-38149125627
49. Saxton W. M., Hollenbeck P. J., The axonal transport of mitochondria. Journal of Cell Science 2012 125 9 2095 2104
50. Li Z., Okamoto K.-I., Hayashi Y., Sheng M., The importance of dendritic mitochondria in the morphogenesis and plasticity of spines and synapses. Cell 2004 119 6 873 887 2-s2.0-10944269186 10.1016/j.cell.2004.11.003 (Pubitemid 40017692)
51. Bernard G., Bellance N., James D., Parrone P., Fernandez H., Letellier T., Rossignol R., Mitochondrial bioenergetics and structural network organization. Journal of Cell Science 2007 120 5 838 848 2-s2.0-34047173074 10.1242/jcs.03381 (Pubitemid 46523485)
52. Du H., Guo L., Yan S., Sosunov A. A., McKhann G. M., Yan S. S., Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proceedings of the National Academy of Sciences of the United States of America 2010 107 43 18670 18675 2-s2.0-78649815388 10.1073/pnas.1006586107
53. Bobba A., Amadoro G., Valenti D., Corsetti V., Lassandro R., Atlante A., Mitochondrial respiratory chain Complexes I and IV are impaired by beta-amyloid via direct interaction and through Complex I-dependent ROS production, respectively. Mitochondrion 2013 13 4 298 311
54. Calkins M. J., Manczak M., Mao P., Shirendeb U., Reddy P. H., Impaired mitochondrial biogenesis, defective axonal transport of mitochondria, abnormal mitochondrial dynamics and synaptic degeneration in a mouse model of Alzheimer's disease. Human Molecular Genetics 2011 20 23 4515 4529 2-s2.0-81255190781 10.1093/hmg/ddr381
55. Tretter L., Sipos I., Adam-Vizi V., Initiation of neuronal damage by complex I deficiency and oxidative stress in Parkinson's disease. Neurochemical Research 2004 29 3 569 577 2-s2.0-1542318096 10.1023/B:NERE.0000014827.94562.4b (Pubitemid 38295007)
56. 2+- stimulated generation of reactive oxygen species by the respiratory chain. Biochemistry 1999 38 40 13279 13287 2-s2.0-0032589515 10.1021/bi9828674 (Pubitemid 29477442)
57. Wang X., Su B., Lee H.-G., Li X., Perry G., Smith M. A., Zhu X., Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. Journal of Neuroscience 2009 29 28 9090 9103 2-s2.0-67650732998 10.1523/JNEUROSCI.1357-09. 2009
58. Manczak M., Calkins M. J., Reddy P. H., Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: implications for neuronal damage. Human Molecular Genetics 2011 20 13 2495 2509 2-s2.0-79958721260 10.1093/hmg/ddr139
59. Mjaatvedt A. E., Wong-Riley M. T. T., Relationship between synaptogenesis and cytochrome oxidase activity in Purkinje cells of the developing rat cerebellum. Journal of Comparative Neurology 1988 277 2 155 182 2-s2.0-0024215686 (Pubitemid 19002129)
60. Jendrach M., Mai S., Pohl S., Vöth M., Bereiter-Hahn J., Short- and long-term alterations of mitochondrial morphology, dynamics and mtDNA after transient oxidative stress. Mitochondrion 2008 8 4 293 304 2-s2.0-53049099984 10.1016/j.mito.2008.06.001
61. Jost C. R., van der Zee C. E. E. M., In 't Zandt H. J. A., Oerlemans F., Verheij M., Streijger F., Fransen J., Heerschap A., Cools A. R., Wieringa B., Creatine kinase B-driven energy transfer in the brain is important for habituation and spatial learning behaviour, mossy fibre field size and determination of seizure susceptibility. European Journal of Neuroscience 2002 15 10 1692 1706 2-s2.0-0036460110 10.1046/j.1460-9568.2002.02001.x (Pubitemid 35471925)
62. Streijger F., Oerlemans F., Ellenbroek B. A., Jost C. R., Wieringa B., van der Zee C. E. E. M., Structural and behavioural consequences of double deficiency for creatine kinases BCK and UbCKmit. Behavioural Brain Research 2005 157 2 219 234 2-s2.0-11444261073 10.1016/j.bbr.2004.07.002 (Pubitemid 40082565)
63. Bürklen T. S., Schlattner U., Homayouni R., Gough K., Rak M., Szeghalmi A., Wallimann T., The creatine kinase/creatine connection to alzheimer's disease: CK-inactivation, APP-CK complexes and focal creatine deposits. Journal of Biomedicine and Biotechnology 2006 2006 11 2-s2.0-33646340668 10.1155/JBB/2006/35936 35936 (Pubitemid 43672669)
64. Iadecola C., Neurovascular regulation in the normal brain and in Alzheimer's disease. Nature Reviews Neuroscience 2004 5 5 347 360 2-s2.0-2342614850 (Pubitemid 38568496)
65. Park L., Anrather J., Zhou P., Frys K., Pitstick R., Younkin S., Carlson G. A., Iadecola C., NADPH oxidase-derived reactive oxygen species mediate the cerebrovascular dysfunction induced by the amyloid β peptide. Journal of Neuroscience 2005 25 7 1769 1777 2-s2.0-14044258771 10.1523/JNEUROSCI.5207-04. 2005 (Pubitemid 40279282)
66. Park L., Zhou P., Pitstick R., Capone C., Anrather J., Norris E. H., Younkin L., Younkin S., Carlson G., McEwen B. S., Iadecola C., Nox2-derived radicals contribute to neurovascular and behavioral dysfunction in mice overexpressing the amyloid precursor protein. Proceedings of the National Academy of Sciences of the United States of America 2008 105 4 1347 1352 2-s2.0-39549106246 10.1073/pnas.0711568105 (Pubitemid 351397056)
67. Leszek J., Sochocka M., Gasiorowski K., Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. Journal of the Neurological Sciences 2012 323 1-2 25 32
68. Luscher T. F., Noll G., The pathogenesis of cardiovascular disease: role of the endothelium as a target and mediator. Atherosclerosis 1995 118 S81 S90 2-s2.0-0029619651 10.1016/0021-9150(95)05667-X (Pubitemid 26027336)
69. Kim H. A., Miller A. A., Drummond G. R., Vascular cognitive impairment and Alzheimer's disease: role of cerebral hypoperfusion and oxidative stress. Naunyn-Schmiedeberg's Archives of Pharmacology 2012 385 10 953 959
70. Sochocka M., Koutsouraki E. S., Gasiorowski K., Leszek J., Vascular oxidative stress and mitochondrial failure in the pathobiology of Alzheimer's disease: new approach to therapy. CNS and Neurological Disorders 2013 12 6 870 881
71. Aliev G., Palacios H. H., Walrafen B., Lipsitt A. E., Obrenovich M. E., Morales L., Brain mitochondria as a primary target in the development of treatment strategies for Alzheimer disease. International Journal of Biochemistry and Cell Biology 2009 41 10 1989 2004 2-s2.0-68949152521 10.1016/j.biocel.2009.03.015
72. Akinyemi R. O., Mukaetova-Ladinska E. B., Attems J., Ihara M., Kalaria R. N., Vascular risk factors and neurodegeneration in ageing related dementias: Alzheimer's disease and vascular dementia. Current Alzheimer Research 2013 10 6 642 653
73. Nelson L., Tabet N., Richardson C., Gard P., Antihypertensives, angiotensin, glucose and Alzheimer's disease. Expert Review of Neurotherapeutics 2013 13 5 477 482
74. Schmieder R. E., Hilgers K. F., Schlaich M. P., Schmidt B. M., Renin-angiotensin system and cardiovascular risk. The Lancet 2007 369 9568 1208 1219 2-s2.0-34047121150 10.1016/S0140-6736(07)60242-6 (Pubitemid 46527856)
75. Saavedra J. M., Angiotensin II AT(1) receptor blockers as treatments for inflammatory brain disorders. Clinical Science 2012 123 10 567 590
76. Mogi M., Iwanami J., Horiuchi M., Roles of brain angiotensin II in cognitive function and dementia. International Journal of Hypertension 2012 2012 7 169649 10.1155/2012/169649
77. Girouard H., Park L., Anrather J., Zhou P., Iadecola C., Angiotensin II attenuates endothelium-dependent responses in the cerebral microcirculation through nox-2-derived radicals. Arteriosclerosis, Thrombosis, and Vascular Biology 2006 26 4 826 832 2-s2.0-33646710114 10.1161/01.ATV.0000205849.22807.6e (Pubitemid 43732158)
78. Kazama K., Anrather J., Zhou P., Girouard H., Frys K., Milner T. A., Iadecola C., Angiotensin II impairs neurovascular coupling in neocortex through NADPH oxidase-derived radicals. Circulation Research 2004 95 10 1019 1026 2-s2.0-8844227341 10.1161/01.RES.0000148637.85595.c5 (Pubitemid 39532332)
79. Capone C., Faraco G., Park L., Cao X., Davisson R. L., Iadecola C., The cerebrovascular dysfunction induced by slow pressor doses of angiotensin II precedes the development of hypertension. The American Journal of Physiology 2011 300 1 H397 H407 2-s2.0-78651313012 10.1152/ajpheart.00679.2010
80. Li N. C., Lee A., Whitmer R. A., Kivipelto M., Lawler E., Kazis L. E., Wolozin B., Use of angiotensin receptor blockers and risk of dementia in a predominantly male population: prospective cohort analysis. BMJ 2010 340 b5465 2-s2.0-74249110813 10.1136/bmj.b5465
81. Davies N. M., Kehoe P. G., Ben-Shlomo Y., Martin R. M., Associations of anti-hypertensive treatments with Alzheimer's disease, vascular dementia, and other dementias. Journal of Alzheimer's Disease 2011 26 4 699 708 2-s2.0-80054843547 10.3233/JAD-2011-110347
82. Takeda S., Sato N., Takeuchi D., Kurinami H., Shinohara M., Niisato K., Kano M., Ogihara T., Rakugi H., Morishita R., Angiotensin receptor blocker prevented β -amyloid-induced cognitive impairment associated with recovery of neurovascular coupling. Hypertension 2009 54 6 1345 1352 2-s2.0-73349097900 10.1161/HYPERTENSIONAHA.109.138586
83. Mogi M., Horiuchi M., Effects of angiotensin II receptor blockers on dementia. Hypertension Research 2009 32 9 738 740 2-s2.0-70249088004 10.1038/hr.2009.110
84. de La Torre J. C., Alzheimer's disease is a vasocognopathy: a new term to describe its nature. Neurological Research 2004 26 5 517 524 2-s2.0-3042730018 10.1179/016164104225016254 (Pubitemid 38879234)
85. Zlokovic B. V., Neurovascular mechanisms of Alzheimer's neurodegeneration. Trends in Neurosciences 2005 28 4 202 208 2-s2.0-13544268809 10.1016/j.tins.2005.02.001 (Pubitemid 40445527)
86. Dong Y. F., Kataoka K., Tokutomi Y., Nako H., Nakamura T., Toyama K., Sueta D., Koibuchi N., Yamamoto E., Ogawa H., Kim-Mitsuyama S., Perindopril, a centrally active angiotensin-converting enzyme inhibitor, prevents cognitive impairment in mouse models of Alzheimer's disease. The FASEB Journal 2011 25 9 2911 2920 2-s2.0-80052647359 10.1096/fj.11-182873
87. Milionis H. J., Florentin M., Giannopoulos S., Metabolic syndrome and alzheimer's disease: a link to a vascular hypothesis? CNS Spectrums 2008 13 7 606 613 2-s2.0-51049085039
88. Drake J., Link C. D., Butterfield D. A., Oxidative stress precedes fibrillar deposition of Alzheimer's disease amyloid β -peptide (1-42) in a transgenic Caenorhabditis elegans model. Neurobiology of Aging 2003 24 3 415 420 2-s2.0-12244281810 10.1016/S0197-4580(02)00225-7 (Pubitemid 36210870)
89. Qiu W. Q., Mwamburi M., Besser L. M., Angiotensin converting enzyme inhibitors and the reduced risk of Alzheimer's disease in the absence of apolipoprotein E4 allele. Journal of Alzheimer's Disease 2013 37 2 421 428
90. Csiszar A., Tucsek Z., Toth P., Synergistic effects of hypertension and aging on cognitive function and hippocampal expression of genes involved in beta-amyloid generation and Alzheimer's disease. The American Journal of Physiology. Heart and Circulatory Physiology 2013 305 8 H1120 H1130
91. LaFontaine M. A., Mattson M. P., Butterfield D. A., Oxidative stress in synaptosomal proteins from mutant presenilin-1 knock-in mice: implications for familial Alzheimer's disease. Neurochemical Research 2002 27 5 417 421 2-s2.0-0036014989 10.1023/A:1015560116208 (Pubitemid 34579349)
92. Bosco D., Fava A., Plastino M., Montalcini T., Pujia A., Possible implications of insulin resistance and glucose metabolism in Alzheimer's disease pathogenesis. Journal of Cellular and Molecular Medicine 2011 15 9 1807 1821 2-s2.0-79960555700 10.1111/j.1582-4934.2011.01318.x
93. 18F]fluorodeoxyglucose. Journal of Computer Assisted Tomography 1983 7 4 590 598 2-s2.0-0020594056 (Pubitemid 13035941)
94. Erdös B., Snipes J. A., Miller A. W., Busija D. W., Cerebrovascular dysfunction in zucker obese rats is mediated by oxidative stress and protein kinase C. Diabetes 2004 53 5 1352 1359 2-s2.0-2342591369 10.2337/diabetes.53.5. 1352 (Pubitemid 38569023)
95. Pasinetti G. M., Eberstein J. A., Metabolic syndrome and the role of dietary lifestyles in Alzheimer's disease. Journal of Neurochemistry 2008 106 4 1503 1514 2-s2.0-48749102434 10.1111/j.1471-4159.2008.05454.x
96. Craft S., The role of metabolic disorders in Alzheimer disease and vascular dementia: two roads converged. Archives of Neurology 2009 66 3 300 305 2-s2.0-62449142597 10.1001/archneurol.2009.27